Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pegpleranib

Bayer symbol

EMA clears Bayer’s Stivarga for liver cancer

The multikinase inhibitor will treat patients with HCC

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

Roche Basel Switzerland

Ocrevus off to a flying start as Roche raises 2017 forecasts

New multiple sclerosis drug posts positive results in first quarter

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Novartis’ CAR-T clears FDA panel with relative ease

Puts tisagenlecleucel-T on course to be first approved personalised CAR-T therapy

- PMLiVE

Shire wins block of Roche’ ‘misinformation’ over emicizumab

Obtains a preliminary injunction from a German court

Bayer symbol

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links